Summary
27.75 -0.01(-0.02%)10/04/2024
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.02 | -1.67 | -5.27 | 8.04 | -3.34 | 4.11 | 0.00 | -35.55 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 27.75 | |
| Open | 27.63 | |
| High | 27.93 | |
| Low | 27.62 | |
| Volume | 1,183,437 | |
| Change | 0.01 | |
| Change % | 0.02 | |
| Avg Volume (20 Days) | 1,145,178 | |
| Volume/Avg Volume (20 Days) Ratio | 1.03 | |
| 52 Week Range | 25.21 - 31.66 | |
| Price vs 52 Week High | -12.37% | |
| Price vs 52 Week Low | 10.06% | |
| Range | 0.42 | |
| Gap Up/Down | -0.53 | |
Fundamentals | ||
| Market Capitalization (Mln) | 12,633 | |
| EBIDTA | 1,679,401,984 | |
| PE Ratio | 19.4964 | |
| PEG Ratio | -0.0200 | |
| WallStreet Target Price | 51.43 | |
| Book Value | 13.4880 | |
| Earnings Per Share | 1.9260 | |
| EPS Estimate Current Quarter | 0.6900 | |
| EPS Estimate Next Quarter | 0.7500 | |
| EPS Estimate Current Year | 2.8300 | |
| EPS Estimate Next Year | 3.1700 | |
| Diluted EPS (TTM) | 1.9260 | |
| Revenues | ||
| Profit Marging | 0.3425 | |
| Operating Marging (TTM) | 0.7246 | |
| Return on asset (TTM) | 0.0614 | |
| Return on equity (TTM) | 0.1540 | |
| Revenue TTM | 2,285,905,920 | |
| Revenue per share TTM | 5.6220 | |
| Quarterly Revenue Growth (YOY) | 0.0880 | |
| Quarterly Earnings Growth (YOY) | -0.6970 | |
| Gross Profit (TTM) | 1,891,514,000 | |
| Dividends | ||
| Dividend Share | 0.6600 | |
| Dividend Yield | 0.0174 | |
| Valuations | ||
| Trailing PE | 19.4964 | |
| Forward PE | 11.6009 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.8004 | |
| Revenue Enterprise Value | 9.0205 | |
| EBITDA Enterprise Value | 11.8904 | |
| Shares | ||
| Shares Outstanding | 429,511,008 | |
| Shares Float | 322,618,608 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 16.30 | |
| Institutions (%) | 62.00 | |
10/01 04:43 EST - fool.com
2 No-Brainer Dividend Stocks to Buy With $100 in October
With their high yields and strong underlying businesses, these stocks are hard to pass up.
2 No-Brainer Dividend Stocks to Buy With $100 in October
With their high yields and strong underlying businesses, these stocks are hard to pass up.
09/28 04:56 EST - fool.com
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
At less than 8 times trailing earnings, Western Union looks like a bargain. Royalty Pharma could grow its specialty financing business much faster than its recent valuation suggests.
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
At less than 8 times trailing earnings, Western Union looks like a bargain. Royalty Pharma could grow its specialty financing business much faster than its recent valuation suggests.
09/16 05:23 EST - fool.com
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Brookfield Renewable Partners offers a juicy dividend yield that could rise steadily along with electricity demand. Royalty Pharma's portfolio of pharmaceutical products is growing by leaps and bounds, and so is its dividend payout.
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Brookfield Renewable Partners offers a juicy dividend yield that could rise steadily along with electricity demand. Royalty Pharma's portfolio of pharmaceutical products is growing by leaps and bounds, and so is its dividend payout.
09/08 04:56 EST - fool.com
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its dividend payout by 46% over the past five years.
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its dividend payout by 46% over the past five years.
09/03 17:14 EST - globenewswire.com
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes
08/28 16:15 EST - globenewswire.com
Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley's 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET.
Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley's 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET.
08/27 12:15 EST - 247wallst.com
Goldman Sachs Predicts a Double-Digit Rally for These 2 Growth Stocks
The tech stock selloff in July surprised the market but not those investors who were paying attention.
Goldman Sachs Predicts a Double-Digit Rally for These 2 Growth Stocks
The tech stock selloff in July surprised the market but not those investors who were paying attention.
08/22 03:04 EST - seekingalpha.com
Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Vertex franchise poses a significant downside risk. That said, Royalty Pharma has solid execution capabilities and is diversifying earnings with new investments. The company raised its 2024 outlook after three quarters of double-digit growth. A solid team, a balance sheet with M&A maneuvers, and an impressive track record make the company a buy.
Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Vertex franchise poses a significant downside risk. That said, Royalty Pharma has solid execution capabilities and is diversifying earnings with new investments. The company raised its 2024 outlook after three quarters of double-digit growth. A solid team, a balance sheet with M&A maneuvers, and an impressive track record make the company a buy.
08/11 18:33 EST - seekingalpha.com
Royalty Pharma: Busy Putting Capital To Work
Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio receipts, driven by sales growth from its cystic fibrosis franchise and other drugs. The company has also been active in acquiring new royalties and investing in various therapeutic areas and is on track to exceed deployment targets.
Royalty Pharma: Busy Putting Capital To Work
Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio receipts, driven by sales growth from its cystic fibrosis franchise and other drugs. The company has also been active in acquiring new royalties and investing in various therapeutic areas and is on track to exceed deployment targets.
08/08 14:14 EST - seekingalpha.com
Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head of Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Chris Hite – Executive Vice President, Vice Chairman Terry Coyne – Executive Vice President, Chief Financial Officer Conference Call Participants Chris Shibutani – Goldman Sachs Hardik Parikh – J.P. Morgan Terence Flynn – Morgan Stanley Michael DiFiore – Evercore Michael Nedelcovych – TD Cowen Di Zhao – UBS Operator Ladies and gentlemen, thank you for standing by.
Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head of Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Chris Hite – Executive Vice President, Vice Chairman Terry Coyne – Executive Vice President, Chief Financial Officer Conference Call Participants Chris Shibutani – Goldman Sachs Hardik Parikh – J.P. Morgan Terence Flynn – Morgan Stanley Michael DiFiore – Evercore Michael Nedelcovych – TD Cowen Di Zhao – UBS Operator Ladies and gentlemen, thank you for standing by.
08/08 12:30 EST - zacks.com
Royalty Pharma (RPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
08/08 09:35 EST - zacks.com
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.85 per share a year ago.
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.85 per share a year ago.
08/05 10:21 EST - zacks.com
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q2 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q2 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
08/01 11:05 EST - zacks.com
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/24 08:30 EST - globenewswire.com
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital.
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital.
07/19 09:50 EST - zacks.com
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
07/19 08:15 EST - globenewswire.com
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
07/17 16:15 EST - globenewswire.com
Royalty Pharma Declares Third Quarter 2024 Dividend
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share.
Royalty Pharma Declares Third Quarter 2024 Dividend
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share.
07/17 10:31 EST - zacks.com
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Royalty Pharma (RPRX) is looking like an interesting pick, as it just reached a key level of support. RPRX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Royalty Pharma (RPRX) is looking like an interesting pick, as it just reached a key level of support. RPRX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
07/15 13:11 EST - zacks.com
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.